New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Gilead Sciences, Inc.

GILD

Healthcare Drug Manufacturers General

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.

Revenue
+6.83%
EPS
−20.2%
Free cash flow
+21.1%
Total debt
+5.17%

Quarter to September 2026, against a year earlier

168.85 2.32 +1.39%
Market cap
$207.8B
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
1.95%
F-score
8/9
ROIC
−4.51%
Net debt / EBITDA
1.4×
Payout ratio
—

Gilead Sciences, Inc. 10-Q filed Oct 30, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 8:09 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 6, 2026: 11 added · 7 removed · 35 modified; 13 with only figures updated; 2 moved without change

  1. Added · Virology

    •In October 2026, the Centers for Medicare and Medicaid Services completed the process of setting the Maximum Fair Price for Biktarvy under Medicare. The new price will be effective and impact our Biktarvy revenue starting January 1, 2028.